Is Ampio Pharmaceuticals, Inc. overvalued or undervalued?

As of 2 August 2016, the valuation grade for Ampio Pharmaceuticals, Inc. moved from risky to does not qualify. The company is currently considered overvalued given its financial metrics and performance. The price-to-book value stands at a mere 0.04, while the EV to EBITDA ratio is 0.40, indicating significant underperformance relative to its peers. Additionally, the return on capital employed (ROCE) is extraordinarily high at 951.80%, but this is misleading due to the negative return on equity (ROE) of -265.51%.
In comparison to its peers, Ampio Pharmaceuticals, Inc. does not qualify with a P/E ratio of -0.0003, while Kinnate Biopharma, Inc. is rated fair with a P/E of -1.1313, and ADC Therapeutics SA is rated risky with a P/E of -2.1005. The stark contrast in valuation and performance metrics suggests that Ampio is not positioned favorably in the market. Furthermore, the company's stock has dramatically underperformed against the S&P 500, with a one-year return of -97.92% compared to the index's 10.26%, reinforcing the notion of overvaluation.